In two Phase I trials, researchers safely administered CAR T cells to high-grade glioma patients and are exploring ways to ...

The company will hold off on making a regulatory decision until it sees results from another trial testing the drug with ...

NEW YORK – Galapagos on Tuesday said that after a strategic review it has decided to wind down its cell therapy business, which includes several CAR T-cell therapies in development for blood cancers ...

The firm will launch a Phase I trial in healthy volunteers in the Netherlands to establish safety and proof-of-target engagement.

In this tough-to-treat cancer type, more patients receiving anzu-cel saw their tumors shrink and had durable responses than what's been seen with other therapies.

The Sweden-based Phase II trial will evaluate how well the company's gallium-68-labeled PET tracer identifies best responders to Enhertu.

While Natera said it will seek FDA approval for Signatera based on data from IMvigor011, the readout from another ctDNA-guided de-escalation study was more nuanced.

The registrational trial of AD04 could launch as early as mid-2026, if the company is able to shore up necessary funds or ...

As Novartis moves ahead plans to expand Pluvicto's use based on the PSMAddition trial, experts urge for greater use of ...

NEW YORK – Taysha Gene Therapies has regained full rights to its lead program, TSHA-102, for Rett syndrome after an option agreement with Astellas expired.

Researchers at the ESMO Congress said they want to confirm their findings in a prospective randomized controlled trial.

The new funds will allow the company to test its multi-node PI3K treatment approach in a new endometrial cancer trial.